Plain-English translation of NCT05415709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new way to deliver , a chemotherapy drug, to people with advanced ovarian, fallopian tube, or peritoneal cancer. You would first receive standard chemotherapy pills and infusions to shrink your cancer, then have surgery. The trial compares two approaches: receiving the day before surgery, or receiving heated directly into your belly during the surgery itself.
Doctors want to find the safest and most effective way to treat advanced ovarian cancer that has spread. By delivering the medication directly into the abdomen and heating it during surgery, researchers hope this may work better and cause fewer side effects than giving it before surgery.
You likely qualify if…
You likely don't qualify if…
You would first receive standard chemotherapy for 3 to 4 cycles (about 9 to 12 weeks), given every 3 weeks. After your cancer responds to this treatment, you would be randomly assigned to one of two groups: one group receives through an IV the day before surgery, and the other group receives heated directly into the abdomen during surgery. You will also provide stool samples and have imaging scans throughout the trial, and answer questions about your quality of life. The study team will follow you for 30 days after your final treatment.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States